Enclomiphene 10 mg (10 mg tablet)

The Next Generation of Testosterone Support

Enclomiphene is the modern, superior alternative to Clomid. It contains only the trans-isomer of clomiphene, which effectively blocks estrogen receptors in the brain to restart your natural testosterone production—without the estrogenic zuclomiphene isomer that causes mood swings and libido issues in standard Clomid.

The gold standard for Post Cycle Therapy (PCT) and Testosterone Replacement Therapy (TRT) alternatives.

Key Benefits:

• Boosts Testosterone: Significantly raises LH and FSH levels.
• Fewer Side Effects: No emotional instability or "weepiness" common with Clomid.
• Maintains Fertility: Supports sperm production.
• Active Recovery: Helps retain gains post-cycle.

Dosage:

• PCT: 12.5mg - 25mg per day for 4-6 weeks.
• Hypogonadism: 12.5mg per day.

1. Description — Clinical summary

Enclomiphene is the trans-isomer of clomiphene and is classified as a selective estrogen receptor modulator (SERM). It has been developed and studied primarily for the treatment of male hypogonadism with the goal of raising endogenous testosterone while preserving spermatogenesis. Enclomiphene 10 mg refers to an oral tablet formulation containing 10 milligrams of the active compound. Clinical trials of enclomiphene (usually at doses in the approximate range of ~12.5–25 mg daily) have shown increases in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and serum testosterone in men with secondary hypogonadism; effects on fertility parameters were generally favorable compared with exogenous testosterone, which suppresses spermatogenesis.

Regulatory status and availability vary by country and over time. Enclomiphene may not be approved for routine clinical use in all jurisdictions. Always check local regulatory approvals and follow prescribing guidance from qualified clinicians.

Note: The information below is educational and does not replace individualized medical advice.

2. How does Enclomiphene work? — Mechanism of action

• Enclomiphene is a SERM that acts primarily at the hypothalamic-pituitary axis.
• It antagonizes estrogen receptors in hypothalamic estrogen-sensitive neurons. This reduces negative feedback from estrogens on the hypothalamus and pituitary.
• Result: increased pulsatile gonadotropin-releasing hormone (GnRH) release → increased pituitary secretion of LH and FSH.
• Increased LH stimulates testicular Leydig cells to produce more endogenous testosterone; increased FSH supports Sertoli cell function and spermatogenesis.
• Because it stimulates the body's own gonadotropin and testosterone production, enclomiphene may raise serum testosterone without the spermatogenic suppression associated with exogenous testosterone therapy.
• Peripheral tissue estrogenic/antiestrogenic effects depend on tissue distribution of estrogen receptors and the SERM profile; enclomiphene is the isomer thought to carry primarily the antiestrogenic hypothalamic action.

3. Dosage — Medical and usage guidelines

General principles and typical clinical approaches (educational overview):

• Indication: most commonly studied for adult men with secondary (central) hypogonadism who desire restoration of endogenous testosterone and preservation of fertility. Use in women and children should follow specialist guidance; contraindicated in pregnancy.
• Typical studied adult male doses: clinical trials frequently used enclomiphene doses in the range of about 12.5–25 mg orally once daily. Enclomiphene 10 mg is a lower dose than commonly reported in trials but could be used as a starting/titration dose under specialist supervision.
• Suggested monitoring-guided approach (example framework used in practice for SERMs):
  • Initiation: start at a clinician-determined dose (for example, 12.5–25 mg once daily in many studies). If using a 10 mg formulation, clinicians may start at 10 mg daily and adjust based on response.
  • Reassessment: measure morning total testosterone, LH, FSH, and estradiol approximately 4–8 weeks after initiation or dose change. Assess symptoms and adverse effects.
  • Dose adjustment: increase or decrease dose based on testosterone level, symptoms, and tolerability. If target testosterone is not achieved and no adverse effects, clinicians may titrate upward within studied ranges. If over-response or side effects occur, reduce dose or discontinue.
  • Duration: individualized; continue only while benefits outweigh risks. Periodic reassessment (e.g., every 3–6 months) is common.
• Fertility: enclomiphene may be preferred over exogenous testosterone when preserving fertility is desired because it tends to maintain or improve sperm production. Semen analysis should be checked if fertility is an objective.
• Special populations:
  • Women: not routinely used without specialist oversight; clomiphene citrate (mixed isomer formulation) is commonly used for ovulation induction in women — enclomiphene’s role in women is limited and should follow specialist recommendations. Contraindicated in pregnancy.
  • Elderly: use with caution and monitor comorbidities.
  • Renal/hepatic impairment: limited data; use caution and monitor; dose adjustments may be necessary under specialist advice.
• Important clinical note: Avoid concurrent exogenous testosterone therapy if the goal is to preserve or restore spermatogenesis because exogenous testosterone suppresses LH/FSH and sperm production.

4. Side effects — Common and rare adverse effects

Common (reported with SERMs and with enclomiphene/clomiphene studies):

• Hot flashes
• Headache
• Nausea, abdominal discomfort
• Mood changes, irritability, insomnia
• Visual disturbances (blurring, spots) — usually reversible but require prompt evaluation
• Increased libido or changes in sexual function
• Gynecomastia or breast tenderness (less common in men compared with women)
• Acne, oily skin
• Changes in serum lipids and liver function tests (occasionally)

Potential and less common/serious adverse effects:

• Elevated hematocrit/polycythemia (secondary to increased testosterone) — monitor hematocrit/hemoglobin
• Thromboembolic events (deep vein thrombosis, pulmonary embolism) — SERMs have been associated with increased thrombotic risk in some settings; evaluate individual risk factors
• Visual disturbances that may persist in rare cases — discontinue and evaluate if vision changes occur
• Mood/psychiatric symptoms (depression, irritability)
• Liver function abnormalities — monitor LFTs if clinically indicated

Contraindications and precautions:

• Known hypersensitivity to enclomiphene or related compounds
• Pregnancy and breastfeeding — contraindicated (can affect fetal development)
• History of thromboembolic disease or high thrombotic risk (use caution)

Monitoring recommendations:

• Baseline and periodic morning total testosterone, LH, FSH
• If fertility is a goal: baseline and periodic semen analyses
• Hematocrit/hemoglobin (monitor for polycythemia)
• Liver function tests and lipid profile as clinically indicated
• Assess for visual changes, mood symptoms, and thrombotic symptoms

If serious adverse effects or signs of thromboembolism, visual loss, or significant mood change occur, discontinue the drug and seek urgent medical evaluation.

5. Storage

• Store at controlled room temperature: approximately 20–25°C (68–77°F). Brief excursions are typically acceptable within about 15–30°C (59–86°F) unless the product labeling specifies otherwise.
• Keep in the original container to protect from moisture and light unless otherwise instructed by the manufacturer.
• Protect from excessive heat and humidity (do not store in bathroom).
• Do not use after the expiration date printed on the packaging. Dispose of unused medication safely according to local regulations.

General safety reminder:
This guide is educational. Specific dosing, monitoring plans, and decisions about starting or stopping enclomiphene should be made by a qualified healthcare professional familiar with the patient’s medical history, laboratory testing, and local regulatory approvals.